Basic Information
| LncRNA/CircRNA Name | MIR100HG |
| Synonyms | NA |
| Region | GRCh38_11:122028327-122556721 |
| Ensemble | ENSG00000255248 |
| Refseq | NR_024430 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | RNA-seq, qPCR, Western blot |
| Sample | cell lines (MDA-MB-231, BT549) |
| Expression Pattern | up-regulated |
| Function Description | we identified lncRNA MIR100HG as a pro-oncogene for TNBC progression. Knockdown of MIR100HG decreased cell proliferation and induced cell arrest in the G1 phase, MIR100HG in The Cancer Genome Atlas (TCGA) and breast cancer cell lines showed higher expression in TNBC than in other tumor types with poor prognosis. |
| Pubmed ID | 30042378 |
| Year | 2018 |
| Title | LncRNA MIR100HG Promotes Cell Proliferation in Triple-Negative Breast Cancer Through Triplex Formation With p27 Loci. |
External Links
| Links for MIR100HG | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |